Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Hua Zhang, PhD, Ling Zhang, PhD, James N. Kochenderfer, MD, Steven A. Rosenberg, MD PhD, Terry J Fry, MD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2016) 128 (22): 218.

https://doi.org/10.1182/blood.V128.22.218.218

Published: 2016

Journal Articles

Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia

Daniel W. Lee, III, MD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Terry J. Fry, MD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, PNP, Hua Zhang, PhD, Ling Zhang, PhD, James N. Kochenderfer, MD, Steven A. Rosenberg, MD PhD, David Stroncek, MD, Crystal L. Mackall, MD

Blood (2015) 126 (23): 684.

https://doi.org/10.1182/blood.V126.23.684.684

Published: 2015

Journal Articles

Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia

Daniel W. Lee, MD, Maryalice Stetler-Stevenson, MD PhD, Marianna Sabatino, MD, Constance Yuan, MD PhD, Terry J Fry, MD, Nirali N Shah, MD, Cindy Delbrook, RN, Bonnie Yates, RN, Hua Zhang, PhD, Ling Zhang, Nick Tschernia, BS, Yongzhi Cui, MD PhD, Steven Feldman, PhD, James N Kochenderfer, MD, Steven A. Rosenberg, MD, PhD, David F. Stroncek, MD, Alan S. Wayne, MD, Crystal L Mackall, MD

Blood (2014) 124 (21): 381.

https://doi.org/10.1182/blood.V124.21.381.381

Published: 2014

Journal Articles

CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers.

Anita K Gandhi, PhD, Derek Mendy, BS, Anastasia Parton, BA, Lei Wu, MS, ECFMG, Jolanta Kosek, BA, Ling-Hua Zhang, PhD, Lori Capone, BS, Antonia Lopez-Girona, PhD, Peter H Schafer, PhD, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 2963.

https://doi.org/10.1182/blood.V120.21.2963.2963

Published: 2012

Journal Articles

Lenalidomide Efficacy in Activated B-Cell-Like Subtype Diffuse Large B-Cell Lymphoma Is Dependent Upon IRF4 and Cereblon Expression

Ling-Hua Zhang, PhD, Jolanta Kosek, BA, Maria Wang, Ph.D., Carla Heise, PhD, Peter H Schafer, PhD, Rajesh Chopra, MD, PhD

Blood (2012) 120 (21): 3287.

https://doi.org/10.1182/blood.V120.21.3287.3287

Published: 2012

Journal Articles

Lenalidomide Displays Anti-Proliferative Activity and Combination Effects with Chemotherapeutic Agents Against a Burkitt’s Lymphoma Cell Line.

Anita K. Gandhi, PhD, Jian Kang, BS, Ling-Hua Zhang, PhD, Blake Bartlett, PhD, Peter H. Schafer, PhD, David I. Stirling, PhD

Blood (2007) 110 (11): 4516.

https://doi.org/10.1182/blood.V110.11.4516.4516

Published: 2007

Journal Articles

Lenalidomide Displays Direct Anti-Non-Hodgkin’s Lymphoma (NHL) Cell Activity in Association with Enhanced SPARC Expression but Independent of Its Ability to Strongly Inhibit NHL Cell VEGF Production In Vitro .

Ling-Hua Zhang, PhD, Peter Schafer, PhD, George Muller, PhD, David Stirling, PhD, J. Blake Bartlett, PhD

Blood (2007) 110 (11): 3473.

https://doi.org/10.1182/blood.V110.11.3473.3473

Published: 2007

Journal Articles

Interleukin-7 Produced by Antigen Presenting Cells Regulates the Homeostatic Peripheral Expansion of Naive CD4 T Cells.

Martin Guimond, PhD, Rachelle G. Veenstra, BA, David J. Grindler, BA, Yongzi Cui, MD/PhD, Risu Na, PhD, Lothar Hennighausen, PhD, Hua Zhang, PhD, Melinda S. Merchant, MD/PhD, Crystal Mackall, MD

Blood (2007) 110 (11): 1333.

https://doi.org/10.1182/blood.V110.11.1333.1333

Published: 2007

Journal Articles

IL7 Administration in Humans Results in Preferential Expansion of Naive and Memory CD4+ & CD8+ T Cells with a Relative Decrease in Regulatory T-Cells (T-Regs).

Claude Sportes, MD, Michael Krumlauf, RN, Rebecca Babb, RN, Ladan Foruraghi, RN, Janine Daub, RN, Daniele Avila, RN, Catherine Chow, MD, Hua Zhang, PhD, Kevin Chua, PhD, Terry Fry, MD, Sarfraz Memon, PhD, Frances Hakim, PhD, Thomas Fleisher, MD, Margaret Brown, BSN, Julie Engel, PhD, Renaud Buffet, MD, Michel Morre, DVM, Ronald Gress, MD, Crystal Mackall, MD

Blood (2006) 108 (11): 871.

https://doi.org/10.1182/blood.V108.11.871.871

Published: 2006

Journal Articles

Comparison of Anti-Angiogenic Activities of Thalidomide and Lenalidomide In Vitro.

Ling-Hua Zhang, PhD, Ling Lu, MS, Lei Wu, MS, Keith Dredge, PhD, J. Blake Bartlett, PhD, Peter Schafer, PhD, George Muller, PhD, Angus Dalgleish, PhD, David Stirling, PhD

Blood (2005) 106 (11): 3959.

https://doi.org/10.1182/blood.V106.11.3959.3959

Published: 2005

Journal Articles

Evaluation of the CD8+ Tumor Associated vs. Non-Tumor Associated Immune Repertoire in Cancer Patients Following Induction of Lymphopenia and Following CD3/4-1BB Based Expansion.

Kristen Snyder, MD, Hua Zhang, PhD, Barbara Vance, PhD, Carl H. June, MD, Robert Vonderheide, MD, PhD, Crystal Mackall, MD

Blood (2005) 106 (11): 2390.

https://doi.org/10.1182/blood.V106.11.2390.2390

Published: 2005

NARROW

Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation

Safety and Response of Incorporating CD19 Chimeric Antigen Receptor T Cell Therapy in Typical Salvage Regimens for Children and Young Adults with Acute Lymphoblastic Leukemia

Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia

CC-122 Is a Novel Pleiotropic Pathway Modifier with Potent in Vitro Immunomodulatory and Anti-Angiogenic Properties and in Vivo Anti-Tumor Activity in Hematological Cancers.

Lenalidomide Efficacy in Activated B-Cell-Like Subtype Diffuse Large B-Cell Lymphoma Is Dependent Upon IRF4 and Cereblon Expression

Lenalidomide Displays Anti-Proliferative Activity and Combination Effects with Chemotherapeutic Agents Against a Burkitt’s Lymphoma Cell Line.

Lenalidomide Displays Direct Anti-Non-Hodgkin’s Lymphoma (NHL) Cell Activity in Association with Enhanced SPARC Expression but Independent of Its Ability to Strongly Inhibit NHL Cell VEGF Production In Vitro .

Interleukin-7 Produced by Antigen Presenting Cells Regulates the Homeostatic Peripheral Expansion of Naive CD4 T Cells.

IL7 Administration in Humans Results in Preferential Expansion of Naive and Memory CD4+ & CD8+ T Cells with a Relative Decrease in Regulatory T-Cells (T-Regs).

Comparison of Anti-Angiogenic Activities of Thalidomide and Lenalidomide In Vitro.

Evaluation of the CD8+ Tumor Associated vs. Non-Tumor Associated Immune Repertoire in Cancer Patients Following Induction of Lymphopenia and Following CD3/4-1BB Based Expansion.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only